

Role of Mitochondrial Bioenergetics in Resilience for Gynecologic Cancer

NCT07046936

Status RECRUITING
Sponsor Wake Forest University Health Sciences
Enrollment 30 participants

Key Eligibility Criteria

Inclusion (5)

- Ability to understand and willingness to sign an IRB-approved informed consent
- Age ≥50 years at the time of enrollment
- Newly diagnosed or suspected FIGO Stage II-IV ovarian/primary peritoneal/fallopian tube carcinoma of any histological subtype OR FIGO Stage II-IV endometrial carcinoma of any histological subtype
- Planned, standard of care treatment consisting of neoadjuvant chemotherapy, tumor reduction surgery, and adjuvant chemotherapy
- Ability to read and understand the English language

Exclusion (4)

- Previously treated for ovarian or endometrial cancer
- History of brain metastases, whole brain irradiation, poorly controlled psychiatric disorders defined by hospitalization within the last 3 months for psychiatric diagnoses, traumatic brain injury, cerebrovascular event, or dementia
- Currently taking anti-amyloid agents, cholinesterase inhibitors, or glutamate regulator
- Documented physical or psychological comorbidity that would limit participant's ability to understand or comply with study procedures for the entire length of the study

Locations (2 total)

Atrium Health Levine Cancer, Charlotte, North Carolina, United States

Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States